Glutathione...not a believer yet????

N

NoExcuses

New member
<div class="FTQUOTE"><begin quote><i>Originally posted by: <b>dramamama</b></i>

Abstract - selected Article

Figures/Tables

References

Purchase PDF (110 K)

E-mail Article

Add to my Quick Links











Related Articles in ScienceDirect

Acute renal failure in CF patients chronically infected...

Journal of Cystic Fibrosis

252 First capsule endoscopy studies in Cystic Fibrosis:...

Journal of Cystic Fibrosis

253 Laparascopic fundoplication is an effective and saf...

Journal of Cystic Fibrosis

View More Related Articles



doi:10.1016/j.jcf.2008.03.006

Copyright © 2008 European Cystic Fibrosis Society Published by Elsevier B.V.

Case Study



Improvement in clinical markers in CF patients using a reduced glutathione regimen: An uncontrolled, observational study



Alfredo Visca, Clark T. Bishop, Sterling C. Hilton and Valerie M. Hudson



Pediatric Pulmonologist, ASL Cuneo 1, Piedmont, Italy - CF Section



Pulmonologist, Provo, Utah, United States



Brigham Young University, United States





Received 19 June 2007; revised 30 January 2008; accepted 14 March 2008. Available online 21 May 2008.



Abstract



CFTR mutation, which causes cystic fibrosis (CF), has also recently been identified as causing glutathione system dysfunction and systemic deficiency of reduced glutathione (GSH). Such dysfunction and deficiency regarding GSH may contribute to the pathophysiology of CF. We followed 13 patients (age range 1 - 27 years) with cystic fibrosis who were using a regimen of reduced glutathione (GSH), including oral glutathione and inhaled buffered glutathione in an uncontrolled, observational study. Dosage ranged from 66 - 148 mg/kg/day in divided doses, and the term examined was the initial 5.5 months of GSH use (45 days of incrementally adjusted dose, plus 4 months of use at full dosage). Baseline and post-measurements of FEV1 percent predicted, BMI percentile, and weight percentile were noted, in addition to bacterial status and pulmonary exacerbations. Significant improvement in the following clinical parameters was observed: average improvement in FEV1 percent predicted (N = 10) was 5.8 percentage points (p < 0.0001), average weight percentile (N = 13) increased 8.6 points (p < 0.001), BMI percentile (N = 11) improved on average 1.22 points (p < 0.001). All patients improved in FEV1 and BMI, if measured in their case; 12 of 13 patients improved in weight percentile. Positive sputum cultures of bacteria in 11 patients declined from 13 to 5 (p < 0.03) with sputum cultures of Pseudomonas aeruginosa becoming negative in 4 of 5 patients previously culturing PA, including two of three patients chronically infected with PA as determined by antibody status. Use of a daily GSH regimen appears to be associated in CF patients with significant improvement in lung function and weight, and a significant decline in bacteria cultured in this uncontrolled study. These findings bear further clinical investigation in larger, randomized, controlled studies.



Keywords: Inflammation; FEV1; BMI; Weight percentile; Pseudomonas aeruginosa



Article Outline</end quote></div>

ya stanford's NAC studies show similar results. Phase III trials will be very informative and exciting!
 
N

NoExcuses

New member
<div class="FTQUOTE"><begin quote><i>Originally posted by: <b>dramamama</b></i>

Abstract - selected Article

Figures/Tables

References

Purchase PDF (110 K)

E-mail Article

Add to my Quick Links











Related Articles in ScienceDirect

Acute renal failure in CF patients chronically infected...

Journal of Cystic Fibrosis

252 First capsule endoscopy studies in Cystic Fibrosis:...

Journal of Cystic Fibrosis

253 Laparascopic fundoplication is an effective and saf...

Journal of Cystic Fibrosis

View More Related Articles



doi:10.1016/j.jcf.2008.03.006

Copyright © 2008 European Cystic Fibrosis Society Published by Elsevier B.V.

Case Study



Improvement in clinical markers in CF patients using a reduced glutathione regimen: An uncontrolled, observational study



Alfredo Visca, Clark T. Bishop, Sterling C. Hilton and Valerie M. Hudson



Pediatric Pulmonologist, ASL Cuneo 1, Piedmont, Italy - CF Section



Pulmonologist, Provo, Utah, United States



Brigham Young University, United States





Received 19 June 2007; revised 30 January 2008; accepted 14 March 2008. Available online 21 May 2008.



Abstract



CFTR mutation, which causes cystic fibrosis (CF), has also recently been identified as causing glutathione system dysfunction and systemic deficiency of reduced glutathione (GSH). Such dysfunction and deficiency regarding GSH may contribute to the pathophysiology of CF. We followed 13 patients (age range 1 - 27 years) with cystic fibrosis who were using a regimen of reduced glutathione (GSH), including oral glutathione and inhaled buffered glutathione in an uncontrolled, observational study. Dosage ranged from 66 - 148 mg/kg/day in divided doses, and the term examined was the initial 5.5 months of GSH use (45 days of incrementally adjusted dose, plus 4 months of use at full dosage). Baseline and post-measurements of FEV1 percent predicted, BMI percentile, and weight percentile were noted, in addition to bacterial status and pulmonary exacerbations. Significant improvement in the following clinical parameters was observed: average improvement in FEV1 percent predicted (N = 10) was 5.8 percentage points (p < 0.0001), average weight percentile (N = 13) increased 8.6 points (p < 0.001), BMI percentile (N = 11) improved on average 1.22 points (p < 0.001). All patients improved in FEV1 and BMI, if measured in their case; 12 of 13 patients improved in weight percentile. Positive sputum cultures of bacteria in 11 patients declined from 13 to 5 (p < 0.03) with sputum cultures of Pseudomonas aeruginosa becoming negative in 4 of 5 patients previously culturing PA, including two of three patients chronically infected with PA as determined by antibody status. Use of a daily GSH regimen appears to be associated in CF patients with significant improvement in lung function and weight, and a significant decline in bacteria cultured in this uncontrolled study. These findings bear further clinical investigation in larger, randomized, controlled studies.



Keywords: Inflammation; FEV1; BMI; Weight percentile; Pseudomonas aeruginosa



Article Outline</end quote></div>

ya stanford's NAC studies show similar results. Phase III trials will be very informative and exciting!
 
N

NoExcuses

New member
<div class="FTQUOTE"><begin quote><i>Originally posted by: <b>dramamama</b></i>

Abstract - selected Article

Figures/Tables

References

Purchase PDF (110 K)

E-mail Article

Add to my Quick Links











Related Articles in ScienceDirect

Acute renal failure in CF patients chronically infected...

Journal of Cystic Fibrosis

252 First capsule endoscopy studies in Cystic Fibrosis:...

Journal of Cystic Fibrosis

253 Laparascopic fundoplication is an effective and saf...

Journal of Cystic Fibrosis

View More Related Articles



doi:10.1016/j.jcf.2008.03.006

Copyright © 2008 European Cystic Fibrosis Society Published by Elsevier B.V.

Case Study



Improvement in clinical markers in CF patients using a reduced glutathione regimen: An uncontrolled, observational study



Alfredo Visca, Clark T. Bishop, Sterling C. Hilton and Valerie M. Hudson



Pediatric Pulmonologist, ASL Cuneo 1, Piedmont, Italy - CF Section



Pulmonologist, Provo, Utah, United States



Brigham Young University, United States





Received 19 June 2007; revised 30 January 2008; accepted 14 March 2008. Available online 21 May 2008.



Abstract



CFTR mutation, which causes cystic fibrosis (CF), has also recently been identified as causing glutathione system dysfunction and systemic deficiency of reduced glutathione (GSH). Such dysfunction and deficiency regarding GSH may contribute to the pathophysiology of CF. We followed 13 patients (age range 1 - 27 years) with cystic fibrosis who were using a regimen of reduced glutathione (GSH), including oral glutathione and inhaled buffered glutathione in an uncontrolled, observational study. Dosage ranged from 66 - 148 mg/kg/day in divided doses, and the term examined was the initial 5.5 months of GSH use (45 days of incrementally adjusted dose, plus 4 months of use at full dosage). Baseline and post-measurements of FEV1 percent predicted, BMI percentile, and weight percentile were noted, in addition to bacterial status and pulmonary exacerbations. Significant improvement in the following clinical parameters was observed: average improvement in FEV1 percent predicted (N = 10) was 5.8 percentage points (p < 0.0001), average weight percentile (N = 13) increased 8.6 points (p < 0.001), BMI percentile (N = 11) improved on average 1.22 points (p < 0.001). All patients improved in FEV1 and BMI, if measured in their case; 12 of 13 patients improved in weight percentile. Positive sputum cultures of bacteria in 11 patients declined from 13 to 5 (p < 0.03) with sputum cultures of Pseudomonas aeruginosa becoming negative in 4 of 5 patients previously culturing PA, including two of three patients chronically infected with PA as determined by antibody status. Use of a daily GSH regimen appears to be associated in CF patients with significant improvement in lung function and weight, and a significant decline in bacteria cultured in this uncontrolled study. These findings bear further clinical investigation in larger, randomized, controlled studies.



Keywords: Inflammation; FEV1; BMI; Weight percentile; Pseudomonas aeruginosa



Article Outline</end quote></div>

ya stanford's NAC studies show similar results. Phase III trials will be very informative and exciting!
 
N

NoExcuses

New member
<div class="FTQUOTE"><begin quote><i>Originally posted by: <b>dramamama</b></i>

Abstract - selected Article

Figures/Tables

References

Purchase PDF (110 K)

E-mail Article

Add to my Quick Links











Related Articles in ScienceDirect

Acute renal failure in CF patients chronically infected...

Journal of Cystic Fibrosis

252 First capsule endoscopy studies in Cystic Fibrosis:...

Journal of Cystic Fibrosis

253 Laparascopic fundoplication is an effective and saf...

Journal of Cystic Fibrosis

View More Related Articles



doi:10.1016/j.jcf.2008.03.006

Copyright © 2008 European Cystic Fibrosis Society Published by Elsevier B.V.

Case Study



Improvement in clinical markers in CF patients using a reduced glutathione regimen: An uncontrolled, observational study



Alfredo Visca, Clark T. Bishop, Sterling C. Hilton and Valerie M. Hudson



Pediatric Pulmonologist, ASL Cuneo 1, Piedmont, Italy - CF Section



Pulmonologist, Provo, Utah, United States



Brigham Young University, United States





Received 19 June 2007; revised 30 January 2008; accepted 14 March 2008. Available online 21 May 2008.



Abstract



CFTR mutation, which causes cystic fibrosis (CF), has also recently been identified as causing glutathione system dysfunction and systemic deficiency of reduced glutathione (GSH). Such dysfunction and deficiency regarding GSH may contribute to the pathophysiology of CF. We followed 13 patients (age range 1 - 27 years) with cystic fibrosis who were using a regimen of reduced glutathione (GSH), including oral glutathione and inhaled buffered glutathione in an uncontrolled, observational study. Dosage ranged from 66 - 148 mg/kg/day in divided doses, and the term examined was the initial 5.5 months of GSH use (45 days of incrementally adjusted dose, plus 4 months of use at full dosage). Baseline and post-measurements of FEV1 percent predicted, BMI percentile, and weight percentile were noted, in addition to bacterial status and pulmonary exacerbations. Significant improvement in the following clinical parameters was observed: average improvement in FEV1 percent predicted (N = 10) was 5.8 percentage points (p < 0.0001), average weight percentile (N = 13) increased 8.6 points (p < 0.001), BMI percentile (N = 11) improved on average 1.22 points (p < 0.001). All patients improved in FEV1 and BMI, if measured in their case; 12 of 13 patients improved in weight percentile. Positive sputum cultures of bacteria in 11 patients declined from 13 to 5 (p < 0.03) with sputum cultures of Pseudomonas aeruginosa becoming negative in 4 of 5 patients previously culturing PA, including two of three patients chronically infected with PA as determined by antibody status. Use of a daily GSH regimen appears to be associated in CF patients with significant improvement in lung function and weight, and a significant decline in bacteria cultured in this uncontrolled study. These findings bear further clinical investigation in larger, randomized, controlled studies.



Keywords: Inflammation; FEV1; BMI; Weight percentile; Pseudomonas aeruginosa



Article Outline</end quote>

ya stanford's NAC studies show similar results. Phase III trials will be very informative and exciting!
 
N

NoExcuses

New member
<div class="FTQUOTE"><begin quote><i>Originally posted by: <b>dramamama</b></i>
<br />
<br />Abstract - selected Article
<br />
<br />Figures/Tables
<br />
<br />References
<br />
<br /> Purchase PDF (110 K)
<br />
<br /> E-mail Article
<br />
<br /> Add to my Quick Links
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />Related Articles in ScienceDirect
<br />
<br /> Acute renal failure in CF patients chronically infected...
<br />
<br />Journal of Cystic Fibrosis
<br />
<br /> 252 First capsule endoscopy studies in Cystic Fibrosis:...
<br />
<br />Journal of Cystic Fibrosis
<br />
<br /> 253 Laparascopic fundoplication is an effective and saf...
<br />
<br />Journal of Cystic Fibrosis
<br />
<br /> View More Related Articles
<br />
<br />
<br />
<br /> doi:10.1016/j.jcf.2008.03.006
<br />
<br />Copyright © 2008 European Cystic Fibrosis Society Published by Elsevier B.V.
<br />
<br />Case Study
<br />
<br />
<br />
<br />Improvement in clinical markers in CF patients using a reduced glutathione regimen: An uncontrolled, observational study
<br />
<br />
<br />
<br />Alfredo Visca, Clark T. Bishop, Sterling C. Hilton and Valerie M. Hudson
<br />
<br />
<br />
<br />Pediatric Pulmonologist, ASL Cuneo 1, Piedmont, Italy - CF Section
<br />
<br />
<br />
<br />Pulmonologist, Provo, Utah, United States
<br />
<br />
<br />
<br />Brigham Young University, United States
<br />
<br />
<br />
<br />
<br />
<br />Received 19 June 2007; revised 30 January 2008; accepted 14 March 2008. Available online 21 May 2008.
<br />
<br />
<br />
<br />Abstract
<br />
<br />
<br />
<br />CFTR mutation, which causes cystic fibrosis (CF), has also recently been identified as causing glutathione system dysfunction and systemic deficiency of reduced glutathione (GSH). Such dysfunction and deficiency regarding GSH may contribute to the pathophysiology of CF. We followed 13 patients (age range 1 - 27 years) with cystic fibrosis who were using a regimen of reduced glutathione (GSH), including oral glutathione and inhaled buffered glutathione in an uncontrolled, observational study. Dosage ranged from 66 - 148 mg/kg/day in divided doses, and the term examined was the initial 5.5 months of GSH use (45 days of incrementally adjusted dose, plus 4 months of use at full dosage). Baseline and post-measurements of FEV1 percent predicted, BMI percentile, and weight percentile were noted, in addition to bacterial status and pulmonary exacerbations. Significant improvement in the following clinical parameters was observed: average improvement in FEV1 percent predicted (N = 10) was 5.8 percentage points (p < 0.0001), average weight percentile (N = 13) increased 8.6 points (p < 0.001), BMI percentile (N = 11) improved on average 1.22 points (p < 0.001). All patients improved in FEV1 and BMI, if measured in their case; 12 of 13 patients improved in weight percentile. Positive sputum cultures of bacteria in 11 patients declined from 13 to 5 (p < 0.03) with sputum cultures of Pseudomonas aeruginosa becoming negative in 4 of 5 patients previously culturing PA, including two of three patients chronically infected with PA as determined by antibody status. Use of a daily GSH regimen appears to be associated in CF patients with significant improvement in lung function and weight, and a significant decline in bacteria cultured in this uncontrolled study. These findings bear further clinical investigation in larger, randomized, controlled studies.
<br />
<br />
<br />
<br />Keywords: Inflammation; FEV1; BMI; Weight percentile; Pseudomonas aeruginosa
<br />
<br />
<br />
<br />Article Outline</end quote>
<br />
<br />ya stanford's NAC studies show similar results. Phase III trials will be very informative and exciting!
 
D

dramamama

New member
Amy-
NAC study showed eradication of PA? I am in contact with a researcher from California and have NOT been advised of this in the NAC study. Please tell us about these results...
 
D

dramamama

New member
Amy-
NAC study showed eradication of PA? I am in contact with a researcher from California and have NOT been advised of this in the NAC study. Please tell us about these results...
 
D

dramamama

New member
Amy-
NAC study showed eradication of PA? I am in contact with a researcher from California and have NOT been advised of this in the NAC study. Please tell us about these results...
 
D

dramamama

New member
Amy-
NAC study showed eradication of PA? I am in contact with a researcher from California and have NOT been advised of this in the NAC study. Please tell us about these results...
 
D

dramamama

New member
Amy-
<br />NAC study showed eradication of PA? I am in contact with a researcher from California and have NOT been advised of this in the NAC study. Please tell us about these results...
 
N

NoExcuses

New member
I was speaking about improvements in overall well-being. Patients in the NAC were not studied for bacteria contents of sputum.

As everybody knows, showing eradication of a bug in sputum culture is no where even close to being accurate. sputum cultures simply show bacteria in the location where sputum is being coughed up.

I would only trust "eradication of PA" if that was demonstrated by a bronch.
 
N

NoExcuses

New member
I was speaking about improvements in overall well-being. Patients in the NAC were not studied for bacteria contents of sputum.

As everybody knows, showing eradication of a bug in sputum culture is no where even close to being accurate. sputum cultures simply show bacteria in the location where sputum is being coughed up.

I would only trust "eradication of PA" if that was demonstrated by a bronch.
 
N

NoExcuses

New member
I was speaking about improvements in overall well-being. Patients in the NAC were not studied for bacteria contents of sputum.

As everybody knows, showing eradication of a bug in sputum culture is no where even close to being accurate. sputum cultures simply show bacteria in the location where sputum is being coughed up.

I would only trust "eradication of PA" if that was demonstrated by a bronch.
 
N

NoExcuses

New member
I was speaking about improvements in overall well-being. Patients in the NAC were not studied for bacteria contents of sputum.

As everybody knows, showing eradication of a bug in sputum culture is no where even close to being accurate. sputum cultures simply show bacteria in the location where sputum is being coughed up.

I would only trust "eradication of PA" if that was demonstrated by a bronch.
 
N

NoExcuses

New member
I was speaking about improvements in overall well-being. Patients in the NAC were not studied for bacteria contents of sputum.
<br />
<br />As everybody knows, showing eradication of a bug in sputum culture is no where even close to being accurate. sputum cultures simply show bacteria in the location where sputum is being coughed up.
<br />
<br />I would only trust "eradication of PA" if that was demonstrated by a bronch.
 
K

ktsmom

New member
<div class="FTQUOTE"><begin quote><i>Originally posted by: <b>NoExcuses</b></i>

As everybody knows, showing eradication of a bug in sputum culture is no where even close to being accurate. sputum cultures simply show bacteria in the location where sputum is being coughed up.



I would only trust "eradication of PA" if that was demonstrated by a bronch.</end quote></div>

I thought one way of obtaining a sputum culture <i>could be</i> via a bronch; in other words a sputum culture doesn't necessarily mean that it was coughed up.
 
K

ktsmom

New member
<div class="FTQUOTE"><begin quote><i>Originally posted by: <b>NoExcuses</b></i>

As everybody knows, showing eradication of a bug in sputum culture is no where even close to being accurate. sputum cultures simply show bacteria in the location where sputum is being coughed up.



I would only trust "eradication of PA" if that was demonstrated by a bronch.</end quote></div>

I thought one way of obtaining a sputum culture <i>could be</i> via a bronch; in other words a sputum culture doesn't necessarily mean that it was coughed up.
 
K

ktsmom

New member
<div class="FTQUOTE"><begin quote><i>Originally posted by: <b>NoExcuses</b></i>

As everybody knows, showing eradication of a bug in sputum culture is no where even close to being accurate. sputum cultures simply show bacteria in the location where sputum is being coughed up.



I would only trust "eradication of PA" if that was demonstrated by a bronch.</end quote></div>

I thought one way of obtaining a sputum culture <i>could be</i> via a bronch; in other words a sputum culture doesn't necessarily mean that it was coughed up.
 
K

ktsmom

New member
<div class="FTQUOTE"><begin quote><i>Originally posted by: <b>NoExcuses</b></i>

As everybody knows, showing eradication of a bug in sputum culture is no where even close to being accurate. sputum cultures simply show bacteria in the location where sputum is being coughed up.



I would only trust "eradication of PA" if that was demonstrated by a bronch.</end quote>

I thought one way of obtaining a sputum culture <i>could be</i> via a bronch; in other words a sputum culture doesn't necessarily mean that it was coughed up.
 
K

ktsmom

New member
<div class="FTQUOTE"><begin quote><i>Originally posted by: <b>NoExcuses</b></i>
<br />
<br />As everybody knows, showing eradication of a bug in sputum culture is no where even close to being accurate. sputum cultures simply show bacteria in the location where sputum is being coughed up.
<br />
<br />
<br />
<br />I would only trust "eradication of PA" if that was demonstrated by a bronch.</end quote>
<br />
<br />I thought one way of obtaining a sputum culture <i>could be</i> via a bronch; in other words a sputum culture doesn't necessarily mean that it was coughed up.
 
You must log in or register to reply here.
Top